Please try another search
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Name | Age | Since | Title |
---|---|---|---|
Hilde Windels | 59 | 2017 | Independent Chairwoman of the Board |
Michel E. J. Lussier | 68 | 2007 | Co-Founder & Executive Director |
Margo R. Roberts | 69 | 2018 | Member of Scientific Advisory Board |
Jean-Christophe Marine | - | - | Member of Scientific Advisory Board |
Marco L. Davila | - | 2016 | Member of Scientific Advisory Board |
Serge Goblet | 66 | 2008 | Non-Executive Director |
Ami Patel Shah | - | 2021 | Non-Executive Director |
Ann Ager | - | - | Member of Scientific Advisory Board |
Andrea Gothing | - | 2024 | Non-Executive Director |
Gerry Graham | - | - | Member of Scientific Advisory Board |
Hinrich Abken | - | 2016 | Member of Scientific Advisory Board |
Christopher LiPuma | - | 2022 | Non-Executive Director |
Marina Udier Blagovic | - | 2020 | Independent Director |
Dominic G. Piscitelli | 49 | 2020 | Independent Director |
John Campbell | - | - | Member of Scientific Advisory Board |
Sage Mandel | - | 2024 | Non-Executive Director |
Jonathan James | - | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review